wave activity on the intraoperative electrocorticogram (ECoG), however, alfentanil was found to be the most potent. These results and others 6±9 showed that short-acting opioids are capable of inducing ECoG activation in epileptic patients. The objective of the current study was to complement the understanding of the potency pro®le of opioidinduced activation by comparing the effects of the newer short-acting opioid remifentanil with those of alfentanil on the ECoG during epilepsy surgery under general anaesthesia.
Methods
With the approval of the hospital research ethics board, informed consent was obtained from patients undergoing craniotomy with resection of an epileptogenic focus. All patients had intractable temporal lobe seizures not controlled by medication. The design was a randomized doubleblind cross-over study. The patients were warned of the possibility of intraoperative awareness when all anaesthetic gases were discontinued during the ECoG recording period.
No premedication was administered. The patients remained on their oral anticonvulsant medications until the day of surgery. Anaesthesia was administered according to a standardized procedure. At induction, propofol 1± 2 mg kg ±1 , fentanyl 3±5 mg kg ±1 and a neuromuscular blocking agent (succinylcholine, atracurium, or rocuronium) were given. Maintenance of anaesthesia consisted of nitrous oxide 70%/oxygen 30%, iso¯urane and with further doses of atracurium or rocuronium as necessary. Routine anaesthetic monitoring was performed, including direct arterial blood pressure monitoring using a radial arterial line. The local anaesthetic bupivacaine 0.5% with epinephrine 1:100 000 was injected at the site of head pin insertion and the surgical wound to lessen the possibility of pain if awareness occurred. The end-tidal partial pressure of carbon dioxide was maintained at 28±30 mm Hg.
After opening the craniotomy, the surgeon positioned three rows of eight contact ECoG electrode strips along the surface of the ®rst and second temporal gyri and immediately above the sylvian ®ssure over the frontocentral neocortex. In addition, two four-contact depth electrodes were inserted orthogonally through the second temporal gyrus with their tips situated to record from the region of the amygdala and anterior hippocampus, respectively. Twenty minutes before ECoG monitoring, iso¯urane was discontinued to lower the seizure threshold and droperidol 0.02 mg kg ±1 administered i.v. to provide some additional sedation.
At the time of the study, nitrous oxide was discontinued and a baseline ECoG was recorded for 10 min. Gas analysis monitoring ensured the end-tidal nitrous oxide and iso¯ur-ane were zero. The study drug (either alfentanil 30 mg kg ±1 or remifentanil 1 mg kg ±1 ) was injected i.v. according to the randomization schedule. The ECoG was again recorded for at least another 10 min after drug administration. When the ECoG had returned to baseline the sequence was then repeated with the second study drug. Blood pressure and pulse rate readings were continuously recorded during the duration of the study. Only the anaesthetist was aware of the identity of the study drug administered and its dosage. After the ECoG recordings were completed, the anaesthetic agents were resumed and the surgical resection performed.
The ECoG recordings were supervised and interpreted by the neurologist (RW) who was present in the operating room and blinded to the study drug. Postoperatively, the druginduced ECoG epileptiform activity was quanti®ed by the neurologist using standard criteria for identi®cation of interictal epileptiform spikes or sharp waves (hereafter referred to as sharp waves). 10 The number of sharp waves per epoch was tabulated from the most active site for each patient. An epoch was arbitrarily identi®ed as a period of 1 min, and the epileptiform activity was quanti®ed for at least 10 epochs (i.e. at least 10 min before and after each drug administration). The baseline activity was de®ned as the median number of spikes per epoch recorded during the 3 min before administration of each study drug. The peak activation of the study drug was the number of spikes at the epoch that showed the maximal effect in the 5 min after administration. ECoG activation was determined by the difference between the baseline spikes per epoch before drug administration subtracted from the peak spikes per epoch observed after drug administration. The percentage activation was calculated according to: [(peak spikes per epoch observed after drug administration ± baseline spikes per epoch before drug administration) / baseline spikes per epoch before drug administration] Q 100. The location in the brain of ECoG activation was recorded as well as any evidence of ictal electrographic seizure activity.
Parametric and non-parametric data are expressed as mean (SEM), and median and range respectively. Changes in blood pressure and heart rate were analysed using the paired Student's t-test with Bonferroni's correction. The Friedman test (non-parametric two-way ANOVA) was used to test the hypothesis that there was no difference between the ECoG activity level (spikes per epoch) before and after administration of both study drugs. Multiple comparisons among baseline, drug effects and recovery were determined using the Wilcoxon signed ranks test. P<0.05 was considered statistically signi®cant.
Results
Thirteen patients consented for the study. They all completed the study procedure. All patients had intractable temporal lobe seizures, 11 had mesial temporal epilepsy and two had temporal neocortical epilepsy associated with a temporal lobe tumour and multiple cavernous angiomas respectively.
The characteristics of the patients were as follows: male/ female ratio 7/6, mean age 30.6 yr (range 20±56) and mean weight 67.5 (3.72) kg. The mean total dose of propofol administered before the beginning of ECoG recording was 208.5 (24.6) mg. The mean dose of droperidol was 1.6 (0.13) mg. The mean total dose of fentanyl given before the administration of the ®rst study drug, and the time interval between the last dose of fentanyl and the administration of the ®rst study drug were 334.62 (27.45) mg and 96.15 (8.48) min, respectively. This indicates that the fentanyl was unlikely to have any measurable effects on the ECoG activation induced by the study drugs, as our previous investigations showed that the action of fentanyl in activating epileptogenic brain tissue lasted for about 10 min. 5 The interval between the administrations of the two study drugs in all patients ranged from 10 to 16 min. The second drug was always given after the ECoG returned to baseline activity in 11 patients or near baseline activity (T15% of baseline) in two patients. The effects of the i.v. bolus of the two study drugs on blood pressure and heart rate are shown in Table 1 . There were no statistical differences in heart rate over the 10-min period after the bolus of either drug. Both remifentanil and alfentanil reduced systolic blood pressure signi®cantly at 3 and 5 min after the bolus. Two patients required doses of a vasoactive drug to maintain systolic blood pressure within 80% of the pre-operative level. One patient required 5 mg of ephedrine after the alfentanil bolus. A second patient received 10 mg of ephedrine after the remifentanil bolus and 5 mg of ephedrine after the alfentanil bolus. The mean Pa CO 2 value during the study period was 32.56 (3.2) mm Hg.
Both opioids signi®cantly increased ECoG epileptiform activity during the 5 min after drug administration (Fig. 1) . When the individual differences in activation of the ECoG were compared, the most potent overall activator was alfentanil (Table 2 ) indicated by the percentage activation The temporal limbic structures (amygdala and/or hippocampus) were the sites most frequently activated by both opioids. In contrast, activation of temporal neocortical epileptiform activity was only evident in the two patients with neocortical structural lesions, and activation of the non-epileptogenic neocortex of the frontocentral region above the Sylvian ®ssure was never seen (Table 3) . In all patients, the localization of the induced epileptiform activity was invariably identical to that of spontaneous spikes recorded in the baseline ECoG, although spike amplitude was often increased by the opioid.
Alfentanil activated the ECoG in two patients in which remifentanil had no effect. In two other patients with mesial temporal lobe epilepsy both opioids decreased the amount of epileptic activity and in this subgroup the opioid bolus was not useful in evaluating the seizure focus. These two patients were included in the ECoG activity analysis shown in Tables 2 and 3 .
Discussion
The present report compared ECoG activation induced by intraoperative administration of alfentanil 30 mg kg ±1 and remifentanil 1 mg kg ±1 in patients undergoing epilepsy surgery. Our procedure ensured minimal carry-over effects of the ®rst drug on the ECoG recordings of the second, while the randomized cross-over design minimized the impact of any such effects in our statistical comparisons of the two drugs. Neither drug had a signi®cant effect on the heart rate, but they caused an equivalent mild reduction in systolic blood pressure. At these doses, alfentanil was more effective in selectively activating interictal epileptiform activity compared with remifentanil. Such opioid induced activation of epileptic activity can assist the surgeon in selecting and con®rming resection location during epilepsy surgery.
Although the results of the present investigation and our previous report 5 con®rm that alfentanil, fentanyl and remifentanil all activate epileptic discharges; they suggest that these short-acting opioids in the doses employed had differing effects on the epileptic thresholds. Among these drugs, alfentanil seems to have more pronounced epileptogenic effects. The reproducibility and dose-dependency of the effects of the short acting opioids on the degree of ECoG activation remains to be determined. For example, in the current study, alfentanil 30 mg kg ±1 produced a similar degree of ECoG activation as did alfentanil 50 mg kg ±1 in our previous study. 5 Moreover, Wass and colleagues 9 showed that intraoperative remifentanil 2.5 mg kg ±1 i.v. bolus injection caused similar ECoG activation compared with remifentanil 1 mg kg ±1 in the present investigation. In previous clinical studies, the short-acting opioids have been found to activate epileptiform activity only in epileptogenic areas in patients with epilepsy. 5 8 9 In the present study, there was no activation of the temporal neocortex except in the two patients with structural lesions situated in the temporal cortex responsible for their neocortical temporal lobe seizures. Most signi®cantly, there was no activation of epileptiform activity recorded in the frontocentral region above the Sylvian ®ssure in any of these patients with temporal lobe epilepsy. This supports the view that the activating properties of the short-acting opioids are speci®c for epileptogenic brain tissue.
11 Despite these observations, only half of the centres using baseline ECoG during epilepsy surgery modify cortical resections based on intraoperative recordings. 12 Hence, further investigations are necessary to evaluate the diagnostic yield of the short-acting opioids in localizing epileptogenic areas and the prognostic advantage of using these drugs.
The proconvulsant properties of opioids may be mediated by directly stimulating both the d-and m-opioid receptors 13 or by enhancing excitatory glutamatergic neurotransmitter activity.
14 The stimulatory opioid actions may also be induced by facilitation of excitatory in¯uences on neuronal networks. Such actions might be a consequence of coupling between excitatory postsynaptic transients and spontaneously spiking epileptogenic neurones or attenuation of inhibitory GABAergic interneurones. 15 16 In conclusion, this study showed that both alfentanil 30 mg kg ±1 and remifentanil 1 mg kg ±1 cause signi®cant activation of epileptogenic areas in epileptic patients undergoing temporal lobe epilepsy surgery. The use of short-acting opioids in temporal lobe epilepsy surgery can assist in distinguishing the epileptogenic zones from nonepileptogenic brain tissue. However, further investigations are necessary to elucidate the rationale of opioid selection and the clinical utility of opioid activation in epilepsy surgery.
